RT Plus EGFR-TKI for Wild-type NSCLC

Clinical trial NCT02738983 · UNKNOWN

Trial details

NCT number: NCT02738983
Sponsor: Hangzhou Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

Start date: 2012-01-01
Primary completion: 2016-12-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.